Global pharmaceutical company Eli Lilly (NYSE: LLY) will be reporting results this Wednesday morning. Here’s what investors should know.
Eli Lilly beat analysts’ revenue expectations last quarter, reporting revenues of $19.8 billion, up 55.5% year on year. It was a stunning quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Is Eli Lilly a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Eli Lilly’s revenue to grow 32.5% year on year, slowing from the 37.6% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Eli Lilly has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Eli Lilly’s peers in the branded pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb delivered year-on-year revenue growth of 5.7%, beating analysts’ expectations by 12.9%, and Corcept reported revenues up 7.3%, falling short of estimates by 1%. Bristol-Myers Squibb traded up 3.5% following the results while Corcept was also up 27.3%.
Read our full analysis of Bristol-Myers Squibb’s results here and Corcept’s results here.
Investors in the branded pharmaceuticals segment have had steady hands going into earnings, with share prices up 1.9% on average over the last month. Eli Lilly is down 6.4% during the same time and is heading into earnings with an average analyst price target of $1,277 (compared to the current share price of $1,123).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
